Herantis Pharma Oyj (HRTIS.HE)
EUR 1.66
(0.91%)
EUR 1.66
(0.91%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 279.84 Thousand EUR | 103.0% |
| 2022 | -9.32 Million EUR | 18.5% |
| 2021 | -23.57 Million EUR | -27.75% |
| 2020 | -9.15 Million EUR | -15.35% |
| 2019 | -8 Million EUR | -112.3% |
| 2018 | -4.17 Million EUR | -93.1% |
| 2017 | -2.16 Million EUR | 51.08% |
| 2016 | -4.42 Million EUR | 72.42% |
| 2015 | -16.04 Million EUR | -92.0% |
| 2014 | -8.35 Million EUR | -970.48% |
| 2013 | -780.62 Thousand EUR | -98.37% |
| 2012 | -393.51 Thousand EUR | 72.79% |
| 2011 | -1.44 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.34 Million EUR | -229.5% |
| 2024 Q2 | -1.34 Million EUR | 0.0% |
| 2023 FY | 279.83 Thousand EUR | 102.63% |
| 2023 Q3 | 1.03 Million EUR | 215.59% |
| 2023 Q4 | 1.03 Million EUR | 0.0% |
| 2023 Q2 | -897.5 Thousand EUR | 0.0% |
| 2023 Q1 | -897.5 Thousand EUR | 50.95% |
| 2022 Q2 | -5.65 Million EUR | -99.51% |
| 2022 Q1 | -2.83 Million EUR | 41.34% |
| 2022 FY | -10.65 Million EUR | 18.5% |
| 2022 Q4 | -3.67 Million EUR | -100.77% |
| 2022 Q3 | -1.82 Million EUR | 67.62% |
| 2021 Q4 | -4.82 Million EUR | -100.04% |
| 2021 Q1 | -3.96 Million EUR | 15.13% |
| 2021 FY | -13.07 Million EUR | -27.75% |
| 2021 Q3 | -2.41 Million EUR | 69.59% |
| 2021 Q2 | -7.93 Million EUR | -100.0% |
| 2020 Q2 | -4.47 Million EUR | -100.01% |
| 2020 Q4 | -4.67 Million EUR | -99.83% |
| 2020 FY | -10.23 Million EUR | -15.35% |
| 2020 Q1 | -2.23 Million EUR | 52.28% |
| 2020 Q3 | -2.34 Million EUR | 47.67% |
| 2019 Q2 | -3.31 Million EUR | -100.0% |
| 2019 Q3 | -2.34 Million EUR | 29.41% |
| 2019 FY | -8.87 Million EUR | -112.3% |
| 2019 Q1 | -1.65 Million EUR | -37.43% |
| 2019 Q4 | -4.68 Million EUR | -100.0% |
| 2018 Q3 | -1.2 Million EUR | -36.85% |
| 2018 Q4 | -1.2 Million EUR | 0.0% |
| 2018 FY | -4.17 Million EUR | -93.1% |
| 2018 Q2 | -882.35 Thousand EUR | 0.0% |
| 2018 Q1 | -882.35 Thousand EUR | -1191.32% |
| 2017 FY | -2.16 Million EUR | 51.08% |
| 2017 Q4 | -68.33 Thousand EUR | 0.0% |
| 2017 Q3 | -68.33 Thousand EUR | 93.26% |
| 2017 Q2 | -1.01 Million EUR | 0.0% |
| 2017 Q1 | -1.01 Million EUR | 45.25% |
| 2016 Q2 | -1.29 Million EUR | 0.0% |
| 2016 FY | -4.42 Million EUR | 72.42% |
| 2016 Q4 | -1.85 Million EUR | -102.73% |
| 2016 Q3 | -913.51 Thousand EUR | 29.66% |
| 2016 Q1 | -1.29 Million EUR | 47.83% |
| 2015 Q3 | -1.22 Million EUR | 81.9% |
| 2015 FY | -16.04 Million EUR | -92.0% |
| 2015 Q1 | -6.79 Million EUR | -129.82% |
| 2015 Q2 | -6.79 Million EUR | 0.0% |
| 2015 Q4 | -2.48 Million EUR | -102.45% |
| 2014 Q1 | -463.1 Thousand EUR | -247.97% |
| 2014 Q3 | -2.95 Million EUR | -6.11% |
| 2014 Q2 | -2.78 Million EUR | -501.46% |
| 2014 Q4 | -2.95 Million EUR | 0.0% |
| 2014 FY | -8.35 Million EUR | -970.48% |
| 2013 FY | -780.62 Thousand EUR | -98.37% |
| 2013 Q4 | -133.08 Thousand EUR | 0.0% |
| 2013 Q1 | -192.9 Thousand EUR | 0.0% |
| 2013 Q3 | -133.08 Thousand EUR | 59.82% |
| 2013 Q2 | -331.24 Thousand EUR | -71.72% |
| 2012 FY | -393.51 Thousand EUR | 72.79% |
| 2011 FY | -1.44 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biohit Oyj | 1.85 Million EUR | 84.882% |
| Nanoform Finland Oyj | -20.75 Million EUR | 101.348% |